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Background
All patients admitted to the Detoxification Unit of the
Programme for Substance Users' Treatment and Rehabili-
tation at the Psychiatric Hospital of Thessaloniki are being
tested for hepatitis B and C and for HIV. Patients also
receive a complete blood and biochemical control as well
as a chest x-ray. In view of the high percentage of hepatitis
C we have developed and implemented a prevention and
treatment programme throughout the various treatment
stages in the facilities of our Programme. There is a four-
sessions health-educational group on hepatitis/HIV/con-
traception, taking place in the Detoxification Unit and
facilitated by nurses. All patients being transferred to the
Therapeutic Community (expected length of stay 1 year)
are referred to a Hepatology Department and receive an
assessment (Virus load count, Ultra-sound and in some
cases liver biopsy) in order to determine the necessity or
not of medication. Patients on medication receive
peginterferone alpha-2b and ribavirin for six months and
regular follow-ups. All patients negative for hepatitis B are
being vaccinated.
Materials and methods
We studied all first admissions only of the years 1999 and
2004 and tried to compare the socio-demographic data.
Results
45% of all first admissions only tested positive for hepati-
tis C in 1999 (85.8% men and 14.2% women) vs 37.6%
(90% men and 10% women) in 2004. Mean age of those
having tested positive was 27.8 years in 1999 and 26.3%
in 2004.
Hepatitis B positive tested only 4% of first admissions in
1999 and 0% in 2004.
There were no HIV-positive cases concerning first admis-
sions either in 1999 or in 2004.
51% of first admissions in 1999 were negative for all
infectious diseases tested vs 62.3% in 2004.
40 patients of the 52 admitted to the Therapeutic Com-
munuty were engaged in the vaccination for hepatitis B.
The rest either refused or had to start the interferone treat-
ment immediately on medical grounds. 27 completed the
vaccination process, the rest interrupted their stay in the
community and their treatment.
All patients positive for hepatitis C have been assessed by
a Hepatology Department and 6 completed or are still
receiving medication.
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The infection rate of hepatitis C shows a decline trend in
Greece between the years 1999 and 2004 and our results
are in concordance to them (41.2–81.6% in 1999 vs 35.8–
67.2% in 2004 according to the treatment modality)
[1,2]. The same applies to hepatitis B. The rates have
declined and remain at very low levels, (whereas the prev-
alence in european countries is 40–70%: 2–6.3% in 1999
vs 2.3–5.8% in 2004) [1,2].
The HIV rate remains surprisingly low in Greece compar-
ing to the other european countries: only 3.9% of all HIV
positive cases reported at the Greek Infectious Diseases
Control Centre until June 2003 were intravenous drug
users. We literally had no cases at all, which doesn't mean
that there aren't any. Most HIV positive cases enter substi-
tution programmes.
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